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Summary
Adult T-cell leukemia/lymphoma (ATL) is a highly aggressive disease with a poor prognosis in which nuclear factor kappa B (NF-κB) is thought to play a role. This study explored the effects of histone deacetylase inhibitors (HDACIs) MS-275, suberoylanilide hydroxamic acid (SAHA), and LBH589 on both human T-cell lymphotropic virus type I (HTLV-1)-infected T cells (MT-1, -2, -4, and HUT102) and freshly isolated ATL cells harvested from patients. HDACIs effectively inhibited the proliferation of these cells. For example, MS-275, SAHA, and LBH589 effectively inhibited the proliferation of MT-1 cells with ED 50s of 6 μM, 2.5 μM, and 100 nM, respectively as measured by 3-(4,5-dimethylithiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay on day 2 of culture. In addition, HDACIs induced cell cycle arrest at the G2/M phase and apoptosis of HTLV-1-infected T-cells in conjunction with regulation of apoptosis-related proteins. Electrophoretic mobility shift assay showed that exposure of HTLV-1-infected T-cells to HDACIs for 48 h inhibited formation of the NF-κB/DNA binding complex. Moreover, we found that HDACIs accumulated NF-κB and inhibitory subunit of NF-κB in the cytoplasm in conjunction with the down-regulation of NF-κB in the nucleus, suggesting that HDACIs blocked nuclear translocation of NF-κB. Based on these findings, we believe HDACIs can be useful for treating patients with ATL or
Introduction
Adult T-cell leukemia (ATL) is an aggressive malignancy of CD4 + T lymphocytes for which human T-cell lymphotropic virus type I (HTLV-I) has been recognized as the etiologic agent [1, 2] . Despite the development of intensive combination chemotherapy regimens supported by granulocyte colony-stimulating factor, the median survival time of individuals with ATL is less than 13 months [3, 4] .
Nuclear factor κB (NF-κB) regulates the expression of anti-apoptotic proteins including Bcl-2 family members as well as X-linked inhibitor of apoptosis protein (XIAP). ATL cells aberrantly express these anti-apoptotic proteins via NF-κB signaling, which is associated with the resistance of these cells to apoptosis mediated by anti-cancer agents [5] [6] [7] .
Histone deacetylase inhibitors (HDACIs) have emerged as a potentially promising new class of anticancer drugs [8] . These include the hydroxamic acid derived suberoylanilide hydroxamic acid (SAHA), LBH 589, and tricostatin A (TSA), cyclic depsipeptide FR901228, and benzamide MS-275 [8] . HDACIs induce the growth arrest and apoptosis of cancer cells by manipulating the transcription of genes involved in regulation of the cell cycle, apoptosis, as well as, differentiation [8] . For example, we previously showed that SAHA induces growth arrest and apoptosis of human mantle Nishioka, et al. 6 cell lymphoma cells in association with induction of the histone acetylation of P21 waf1 promoter region, resulting in the up-regulation of P21 waf1 protein [9] .
Recently, a new mode of action for HDACIs has been identified in which TSA and FR901228 inhibit NF-κB/DNA binding activity in HTLV-1-infected T-cells and murine epidermal skin JB6, respectively [5, 10] . However, the precise mechanism by which HDACIs inhibit NF-κB remains to be fully elucidated.
This study explored the effects of the HDACIs MS-275, SAHA, and LBH589
on NF-κB signaling in HTLV-1-infected T-cells. Exposure of these cells to HDACIs increased their levels of inhibitory subunit of NF-κB (IκB) and NF-κB in the cytoplasm in conjunction with the down-regulation of NF-κB in the nucleus, resulting in the inhibition of NF-κB signaling and induction of apoptosis of these cells.
Materials and Methods.
Cells. HTLV-1-infected T-cell lines MT-1, MT-2, and MT-4 were the kind gifts of I.
Miyoshi (Kochi Medical School, Kochi, Japan). MT-1 is a leukemia T-cell line established from the leukemia cells of a ATL patient with the disease [1] . MT-2 and -4
are HTLV-1-transformed cell lines established using an in vitro co-culture protocol [11] . After culture, cell number and viability were evaluated by measuring the mitochondrial-dependent conversion of the 3-(4,5-dimethylithiazol-2-yl)-2,5-diphenyl tetrazolium salt (MTT) (Sigma) to a colored formazan product.
Cell Cycle analysis by Flow Cytometry. Cell cycle analysis was performed as previously described [12] .
Apoptosis Assays. The ability of HDACIs to induce apoptosis of HTLV-1-infected T-cells was measured using an annexin V-FITC apoptosis detection kit according to the manufacturer's instructions (Pharmingen, Inc., San Diego, CA).
Electrophoretic Mobility Shift Assay (EMSA).
Electrophoretic mobility shift assay (EMSA) was done as previously described [13] . Briefly, 4 μg of nuclear extract was incubated with 16 fmol 32 P-end labeled NF-κB binding probe. The DNA-protein complex was separated from the free oligonucleotide on a 5% polyacrylamide gel. Gels were dried and exposed to Kodak XAR film (Eastman Kodak, New Haven, CT).
Western Blot Analysis. Western blot analysis was performed as described previously [12] . Protein concentrations were quantitated using a Bio-Rad assay (Bio-Rad Laboratories, Hercules, CA). Proteins were resolved on a 10% SDS polyacrylamide gel, Statistical analysis. Statistical analyses were carried out by paired t-test using SPSS software (SPSS Japan, Tokyo, Japan). The results were considered to be significant when the P-value was < 0.05, and when the P-value was < 0.01, highly significant.
Results.

Effect of HDACIs on HTLV-1-infected T-cells.
To examine the effects of HDACIs on the growth of HTLV-1-infected T-cells, we cultured these cells in the presence of various concentrations of either MS-275 (0.1-6 μM), SAHA (0.1-5 μM) or LBH589 (10-1000 nM). Cell viability was assessed using the MTT assay on day 2 of culture, and the results were graphed and the effective dose that inhibited 50 % growth (ED50) of these cells was calculated (Fig 1) ( Table 1) . SAHA also effectively inhibited growth of the HTLV-1-infected T-cells (ED50 ranging from 2.7 to 8.8 μM) (Fig 1C, Table 1 ).
MS-275 inhibited the growth of MT-1, -2, and -4 cells with an ED50 of approximately 6
μM (Fig 1A,
Effect of MS-275 on the cell cycle distribution of HTLV-1-infected T-cells.
To investigate the mechanisms by which MS-275 inhibited the growth of HTLV-1-infected T-cells, we analyzed the cell cycle distribution after exposure of these cells to MS-275 (Fig 2) . MS-275 (3 or 6 μM, 48h) prominently induced the accumulation of HTLV-1-infected T-cells at the pre-G1 phase of the cell cycle, a feature characteristic of apoptosis, with a concomitant decrease in the proportion of cells in the S phase (Fig 2) . In addition, MS-275 increased the percent of cells in the G2/M phase (Fig 2) . For example, exposure of MT-1 or -2 cells to MS-275 (3 μM, 48 h) caused the accumulation of the mean 19 ± 7 and 32 ± 7 % cells in G2/M phase of the cell cycle versus a mean 8 ± 3 and 19 ± 6 % in the diluent treated control cells, respectively (Fig   2) .
MS-275 induced apoptosis of HTLV-1-infected T-cells.
To confirm further the ability of MS-275 to induce apoptosis of HTLV-1-infected T-cells, annexin V staining was utilized (Fig 3) . Annexin V binds to cells that express phosphatidylserine on the outer layer of the cell membrane, a characteristic of cells entering apoptosis [14] . Exposure of HTLV-1-infected T-cells to MS-275 (6 μM, 48h)
profoundly increased the population of cells that became positive for Annexin V (32-67 %) (Fig 3) .
Effect of HDACIs on cell cycle and apoptosis-related proteins in HTLV-1-infected
T-cells. We next examined whether HDACIs modulated the cell cycle and the level of apoptosis-related proteins in HTLV-1-infected T-cells by Western blot analysis (Fig 4) .
HTLV-1-infected T-cells aberrantly expressed XIAP, which was consistent with previous studies [6] , and exposure of these cells to MS-275 (3 or 6 μM, 48 h) prominently decreased levels of this anti-apoptotic protein (Fig 4A) . Expression of p21 waf1 was not detectable in MT-1 and HUT102 cells ( Fig 4A) ; exposure of these cells to MS-275 (3 or 6 μM, 48 h) dramatically induced p21 waf1 levels (Fig 4A) . MT-2 and -4 cells slightly expressed p21 wa f1 protein, which dramatically increased after exposure to MS-275 (3 or 6 μM, 48 h) (Fig 4A) . Similarly, LBH589 or SAHA decreased levels of XIAP in conjunction with the up-regulation of p21 wa f1 in MT-1 and -4 cells (Fig 4B) .
XIAP is a key member of the apoptosis protein family inhibitors, which block apoptosis by blocking the activity of caspase-3, -7, and -9 [14] . We, therefore, examined whether down-regulation of XIAP correlate with activation of caspases. As expected, cleavage of caspase 3, indicating activation of this cysteine protease, was apparently induced after exposure to MS-275 (3 or 6 μM, 48 h) (Fig 4A) . Modulation of the levels of Bcl-2 family members in HTLV-1-infected T-cells after exposure to MS-275 was cell-type specific (Fig 4A) . MS-275 (3 or 6 μM, 48 h) increased levels of Bcl-2 and Bcl-xL in MT-1 and -2 cells, while these proteins were down-regulated in HUT102 cells (Fig 4A) .
Exposure of MT-4 cells to MS-275 (3 or 6 μM, 48 h) decreased levels of Bcl-xL, while levels of Bcl-2 were not modulated in these cells (Fig 4A) .
Effect of HDACIs on NF-κ κ κ κB activity in HTLV-1-infected T-cells.
XIAP is one of the NF-κB target genes [14] . Thus, we examined whether HDACIs affected NF-κB activity in HTLV-1-infected T-cells by utilizing EMSA (Fig 5) .
Exposure of MT-1 cells to either MS-275 (6 μM, 48 h), LBH589 (100 nM, 48h), or SAHA (5 μM, 48h) almost completely disrupted formation of the NF-κB/DNA binding complex (Fig 5) . Similarly, MS-275 (6 μM, 48 h) completely inhibited NF-κB/DNA binding formation in MT-4 cells (Fig 5) . MS-275 (6 μM, 48 h) also interfered with formation of the NF-κB/DNA binding complex in HUT102 and MT-2 cells, although the effect was less dramatic compared to that occurred with the other cell lines (Fig 5) .
The specificity of the NF-κB band was confirmed by competing with 100-times molar excess of unlabeled wild type oligonucleotides, but not mutated oligonucleotides (Fig.   5 ).
Activation of NF-κB involves two important steps: First, the phosphorylation and subsequent degradation of IκBα caused by IκB kinase, resulting in the release of NF-κB; and second, the nuclear translocation of the activated NF-κB. To elucidate the effect of MS-275 on these steps, we measured the levels of NF-κB proteins in the cytoplasm and nucleus of the HTLV-1-infected T-cells after their exposure to MS-275 (Fig 6) . IκBα and NF-κB accumulated in the cytoplasm (Fig 6A) . Concomitantly, levels of NF-κB prominently decreased in the nucleus (Fig 6B) , suggesting that MS-275 blocked translocation of NF-κB from the cytoplasm to the nucleus.
MS-275 induced growth arrest and apoptosis of ATL cells freshly isolated from
patients. We explored the effect of MS-275 on ATL cells freshly isolated from patients with acute-type ATL (Table 2) . ATL cells were cultured in the presence of various concentrations of MS-275 (0.5-6 μM). After 48 h, MTT activity and the proportion of cells positive for annexin V staining were measured; exposure of these cells to MS-275 induced growth arrest and apoptosis in a dose-dependent manner (Fig 7) . On the other hand, MS-275 (0.5-6 μM) did not affect the viability of CD4 + T lymphocytes from healthy volunteers (n=3, data not shown).
Discussion.
This study shows that the MS-275, SAHA, and LBH589 HDACIs induced growth arrest and apoptosis of ATL cells in association with the blockade of signaling by NF-κB. Previous study has shown that the blockade of NF-κB by either the diterpenoid oridonin [15] , the proteasome inhibitor Velcade (Bortezomib) [16] , or the NF-κB is involved in producing proinflammatory cytokines. Targeting this transcriptional factor may be an attractive strategy for treating inflammatory diseases.
For example, we were able to rescue mice from lipopolysaccharide (LPS)-induced septic shock by blocking NF-κB signaling by the eight herbal mixture PC-SPES [13] .
Recent preclinical studies have raised the possibility that HDACIs may be used for inflammatory diseases since SAHA decreased the LPS-stimulated production of proinflammatory cytokines in murine macrophages [22] . In a murine lupus erythematosus model, SAHA decreased production of proinflammatory cytokines such as interleukin-6 (IL-6) and -10 and decreased glomerulonephritis [23] . SAHA also prevented graft-versus-host disease in a murine bone marrow transplantation model by reducing the production of proinflammatory cytokines [24] . Interestingly, SAHA preserved the reactivity of donor-lymphocytes against host antigens [24] . We expect that
HDACIs can block exaggerated cytokine production in lymphocytes and macrophages by inhibiting NF-κB. Nevertheless, additional studies are required to clarify all of the molecular mechanisms by which SAHA decreases cytokine production in the above-mentioned model systems.
In Three repeated experiments yielded similar results. WT, wild type and mt, mutant oligonucleotides (100 x) were used to compete the cellular lysate NF-κB binding to the labeled oligonucleotides. SAHA, suberoylanilide hydroxamic acid; N.R., not reached. 
